Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman
Portfolio Pulse from
Regeneron Pharmaceuticals is experiencing challenges with disappointing sales, legal issues, and analyst downgrades. TD Cowen has reduced its price target for Regeneron due to increased competition and lower revenue estimates for its product EYLEA®.
February 21, 2025 | 6:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals is under pressure due to disappointing sales, legal challenges, and a price target downgrade by TD Cowen. The downgrade is attributed to increased competition and lower revenue estimates for EYLEA®.
The news highlights multiple negative factors affecting Regeneron, including disappointing sales, legal issues, and a significant price target downgrade by TD Cowen. These factors are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100